Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Oncology Today with Dr Neil Love
00:00
Choosing Between Approved Oral SERDs
Joyce contrasts imlunestrant and elacestrant, noting CNS activity, pure antagonism, tolerability, and scenarios favoring each drug.
Play episode from 28:04
Transcript
